Physical stability comparisons of IgG1-Fc variants: effects of N-glycosylation site occupancy and Asp/Gln residues at site Asn 297 by Alsenaidy, Mohammad A. et al.
Physical stability comparisons of IgG1-Fc variants: effects of N-
glycosylation site occupancy and Asp/Gln residues at site Asn 
297
MOHAMMAD A. ALSENAIDY#1, SOLOMON Z. OKBAZGHI#, JAE HYUN KIM, SANGEETA B. 
JOSHI, C. RUSSELL MIDDAUGH, THOMAS J. TOLBERT*, and DAVID B. VOLKIN*
Department of Pharmaceutical Chemistry, Macromolecule and Vaccine Stabilization Center, 
University of Kansas, Lawrence, Kansas 66047, USA
# These authors contributed equally to this work.
Abstract
The structural integrity and conformational stability of various IgG1-Fc proteins produced from 
the yeast Pichia pastoris with different glycosylation site occupancy (di-, mono-, and non- 
glycosylated) was determined. In addition, the physical stability profiles of three different forms of 
non-glycosylated Fc molecules (varying amino acid residues at site 297 in the CH2 domain due to 
point mutations and enzymatic digestion of the Fc glycoforms) were also examined. The physical 
stability of these IgG1-Fc glycoproteins was examined as a function of pH and temperature by 
high throughput biophysical analysis using multiple techniques combined with data visualization 
tools (three index empirical phase diagrams and radar charts). Across the pH range of 4.0 to 6.0, 
the di- and mono- glycosylated forms of the IgG1-Fc showed the highest and lowest levels of 
physical stability respectively, with the non-glycosylated forms showing intermediate stability 
depending on solution pH. In the aglycosylated Fc proteins, the introduction of Asp (D) residues at 
site 297 (QQ vs. DN vs. DD forms) resulted in more subtle changes in structural integrity and 
physical stability depending on solution pH. The utility of evaluating the conformational stability 
profile differences between the various IgG1-Fc glycoproteins is discussed in the context of 
analytical comparability studies.
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Introduction
Monoclonal antibodies (mAbs) are well established as the leading class of protein-based 
drugs due to their high target specificity and long half lifes.1, 2 The majority of mAbs 
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developed to date are IgG1 proteins, consisting of four polypeptide chains (two heavy and 
two light chains) that arrange into 12 Ig domains that form into a Y-shaped molecule with 
two antigen binding (Fab) regions and one crystallizable (Fc) region. The homodimeric, 
horseshoe shaped, Fc region contains two interacting CH3 domains at the C-terminal ends 
and two CH2 domains at the N-terminal ends of the molecule. The two CH2 domains interact 
with each other through two buried N-linked glycosylation sites located at Asn 297. 3, 4
Glycosylation of the Asn 297 residue is one of the most common post-translational 
modifications found within mAbs. In the past few years, we have seen rapid growth in our 
understanding of the role of glycosylation with regard to both biological activity and 
pharmaceutical properties. Conformational changes of the CH2 domain, as a result of fully 
or partially removing the glycan residues, have been found responsible for altering the 
functionality3, physicochemical stability 5-8 and pharmacokinetic profile 9 of various mAbs. 
Additionally, protease resistance (using papain) has been shown to be significantly lowered 
in deglycosylated mAbs.10-11 These observations have been attributed to conformational 
differences due to the loss of both glycan-glycan and glycan-protein backbone non-covalent 
interactions upon deglycosylation. This results in the deglycosylated mAb to adopt a more 
open conformational state.
Mass spectrometric analyses of glycopeptides from mAbs have revealed significant 
heterogeneity in terms of glycosylation patterns of both currently marketed mAbs and those 
under development, depending on a variety of factors including the antibody type, 
expression systems and cell culture conditions.12-16 Among these glycoforms are the high 
mannose (HM) glycans consisting of 3 to 12 mannose units connected to two core GlcNAc 
units (N-acetyl glucosamine). In one study, an analysis of the glycan heterogeneity in 
Rituximab (a currently marketed drug for the treatment of non-Hodgkin's lymphoma) 
revealed that 1.7-5.4 % of the glycans present were of a HM nature. 17 Antibodies 
containing HM glycans are known to have faster clearance times compared to glycans 
having either GlcNAc, galactose or sialic acid units at the non-reducing termini of the 
oligosaccharide.18, 19 The effect of having enriched or depleted levels of HM IgG1 within a 
heterogeneous mixture of IgG1 glycoforms was shown to not affect the physical stability of 
the mAb preparation.20 Asymmetric mAb glycosylation (single arm glycosylation) has been 
reported for an IgG1 containing a single glycosylation in the Fab region.21 This results in the 
IgG1 losing its divalent binding capacity to its antigen. An asymmetrically glycosylated 
IgG1 in the CH2 domain was isolated and characterized by Ha et. al. (2011). 22 The authors 
purified the monoglycosylated form of the IgG1 to ~80-85%. Although minimal stability 
differences were noted by DSC at one solution pH (1°C lower for Tm1 and no difference for 
Tm2), Fc gamma receptor binding activity differences between the asymmetrically and the 
fully glycosylated IgG1 of 2-3 fold were reported. Comparisons of the physical stability 
profiles of a variety of different proteins have been performed in our laboratories recently 
including ten mutants of acidic fibroblast growth factor,23 three glycoforms of an IgG1 mAb 
generated by deglycosylation,24 and fifteen different formulations of GCSF protein.25 In this 
work, IgG1-Fc glycoforms containing well defined, homogeneous glycosylation patterns, 
produced using a Pichia pastoris yeast expression system followed by purification and 
specific enzymatic digestions, were utilized to more directly address the effect of 
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glycosylation site occupancy and amino acid substitution (at Asn 297, the N-linked 
glycosylation site in CH2 domain) on the structural integrity and conformational stability of 
a human IgG1-Fc. The physical stability of this series of Fc glycoproteins was examined by 
high throughput biophysical analysis using multiple analytical techniques combined with 
data visualization tools (three-index empirical phase diagrams and radar charts). By using 
larger physical stability data sets acquired from multiple high throughput low-resolution 
biophysical techniques as a function of environmental stresses (pH and temperature), 
differences in the structural integrity and conformational stability in this series of Fc 
glycoforms were detected. These stability trends, as a function of site occupancy and amino 
acid substitution in the Fc glycoforms, were not necessarily observed using the same 
biophysical techniques under non stressed conditions. As a result, evaluating the 
conformational stability differences between the different IgG1-Fc glycoproteins may serve 
as a surrogate to monitor differences in higher-order structure between IgG1-Fc samples, an 
approach that could potentially be useful for analytical comparability studies.
Materials and Methods
Materials
Both the human IgG1-Fc sequence (comprising 446 amino acids with a theoretical 
molecular weight of 50132.92 Da) and a point mutant of the IgG1-Fc protein (with 446 
amino acids and a theoretical molecular weight of 50160.96 Da) were prepared and 
expressed using a glycosylation deficient strain of Pichia pastoris as described by Xiao et. 
al. (2009).26 The nonglycosylated variant of the IgG1-Fc was made by mutating the N-
linked glycosylation site at Asn 297 (EU numbering) to Gln 297, thus eliminating the Asn-
X-Thr glycosylation site within the CH2 domain. This was achieved through PCR site-
directed mutagenesis using Quikchange II site-directed mutagenesis kit (Agilent 
Technologies), followed by transfecting the yeast with the mutated plasmid after sequencing 
it for verification as described by Xiao et. al. (2009).26 After expression, purification and 
concentration of the different IgG1-Fc glycoproteins (as described below), samples were 
dialyzed into the storage buffer (10 % sucrose, 20 mM histidine, pH 6.0) and frozen at -80 
°C in aliquots of 0.5 mL. For the initial characterization of the IgG1-Fc proteins (SDS-
PAGE, mass spectroscopy and SE-HPLC), samples were analyzed without further dialysis. 
For biophysical characterization (far-UV circular dichroism, intrinsic/extrinsic fluorescence 
spectroscopy and turbidity measurements), samples were dialyzed against 20 mM citrate 
phosphate buffer (pH 4.0-6.0, 0.5 increments) and adjusted to an ionic strength of 0.15 with 
NaCl. Other chemicals and reagents not described below were obtained from Sigma–Aldrich 
(St. Louis, MO), Fisher Scientific (Pittsburg, PA), Invitrogen (Carlsbad, California) or 
Becton Dickinson and Company (Franklin Lakes, NJ).
Methods
Expression and purification of the IgG1-Fc proteins—IgG1-Fc proteins were 
cloned and then expressed using an OCH1 deleted strain of Pichia pastoris yeast expression 
system, followed by Protein G affinity purification, as described previously.26 To separate 
the differentially glycosylated forms of the IgG1-Fc, two different purification methods 
were used as described below. Since the purity of the IgG1-Fc variants was essentially the 
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same from methods (data not shown), the purified fractions from each approach were 
combined (for each variant separately) to ensure the same material was being examined 
during biophysical studies.
First, a cation exchange chromatography (CEX) method using ProPac WCX-10 semi-
preparative (9 × 250 mm) column, (Dionex, Sunnyvale, CA) was utilized.27 The column 
was equilibrated with Buffer A (20 mM sodium acetate pH 4.8) for 5 column volumes (CV). 
The protein G purified IgG1-Fc solution was then loaded onto the cation exchange column. 
Chromatographic separation was then performed in a linear gradient from 0 to 1M NaCl (10 
CV) using Buffer B (20 mM sodium acetate pH 4.8, 1 M NaCl). Two mL fractions were 
collected throughout the gradient. Peaks were collected corresponding to the diglycosylated 
and monoglycosylated IgG1-Fc proteins (which are primarily used in this study and 
represented ~80% and ~15% of the material, respectively) in addition to an aglycosylated 
IgG1-Fc form (~5% of the material). After analyzing column fractions with SDS-PAGE to 
confirm glycoprotein identity, the two collected IgG1-Fc glycoforms were concentrated, 
dialyzed against 10% sucrose, 20 mM histidine pH 6.0 and frozen at -80 °C until further use.
For the second, scaled-up purification process, a hydrophobic interaction chromatography 
(HIC) method using a HiScreen fast flow phenyl sepharose column (4.7 mL bed volume and 
7.7×100 mm bed dimensions, GE Healthcare) was adopted.26 The HIC column was 
equilibrated with Buffer A (20 mM sodium phosphate, 1M ammonium sulfate pH 7.0) for at 
least 5 CV. The protein G purified IgG1-Fc solution was then loaded onto the HIC column. 
Chromatographic separation was then conducted in a linear gradient from 1.0 to 0 M 
ammonium sulfate (10 CV) using Buffer B (20 mM sodium phosphate, pH 7.0). Ten mL 
fractions were collected throughout the gradient. Two peaks were observed and collected 
corresponding to the diglycosylated and monoglycosylated glycoforms of the IgG1-Fc 
proteins. After analyzing column fractions with SDS-PAGE, the collected glycoforms were 
concentrated, dialyzed against storage buffer (10% sucrose, 20 mM histidine pH 6.0) and 
frozen at -80 °C until further use.
Since the nonglycosylated (NN at site 297) form of the IgG1-Fc was difficult to purify and 
could only be produced in low, insufficient amounts, a nonglycosylated (QQ at sites 297) 
IgG1-Fc point mutant protein was expressed, using an OCH1 deleted Pichia pastoris strain, 
and purified in a similar fashion to that described above including the HIC purification 
method.26
Deglycosylation of IgG1-Fc glycoproteins—The purified diglycosylated and 
monoglycosylated forms of the IgG1-Fc were deglycosylated using the enzyme peptide-N-
Glycosidase F (PNGase F) under non-denaturing conditions (made in-house as described 
elsewhere).28 Samples in storage buffer were thawed, treated with PNGase F in a protein to 
enzyme ratio of 500:1 (w/w) and incubated for 6 hrs. at 25 °C. Enzymatic reaction 
completion was confirmed by MS and SDS-PAGE analysis (see Table 1 and supplementary 
Figures S1 and S2).
Electrospray Ionization-Mass Spectrometry—IgG1-Fc proteins were analyzed by 
electrospray ionization mass spectrometry (ESI-MS). ESI spectra of reduced protein samples 
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(15 mM dithiothreitol, pH 7.0, room temperature) were acquired on a SYNAPT G2 hybrid 
quadrupole / ion mobility / time of flight mass spectrometer (Waters Corp., Milford, MA). 
The instrument was operated in a sensitivity mode with all lenses optimized on the MH+ ion 
obtained from Enkephalin. The sample cone voltage was 30eV. Argon was admitted to the 
trap cell that was operated at 4eV for maximum transmission. Spectra were acquired at 9091 
Hz pusher frequency covering the mass range from 100 to 3000 u and accumulating data for 
1.5 seconds per cycle. Time to mass calibration was made with Nal cluster ions acquired 
under the same conditions. Samples were desalted on a reverse phase C4 column, 1 cm, 1 
mm I.D. (Vydac, Midland, Canada, 300 A pore size. The 5 μm particles were packed by 
Micro-Tech Scientific) using a NanoAcquity chromatographic system (Waters Corp., 
Milford, MA). The solvents used were A (99.9% H2O, 0.1% formic acid) and B (99.9% 
acetonitrile, 0.1% formic acid). A short gradient was developed from 1 to 70% B in 4 min 
with a flow rate of 20 μl/min. Masslynx 4.1 software was used to collect the data. The 
MaxEnt 1routine was used for processing data to convert peaks of multiply charged protein 
ions into uncharged deconvoluted protein spectra.
Binding of IgG1-Fc glycoforms to Fc γ receptor IIIA—The interactions of the 
different IgG1-Fc proteins with Fc γ receptor IIIA (FcγRIIIA) were studied with bio-layer 
interferometry using a BLITZ instrument (Fortebio, Menlo Park, CA) with protein G 
biosensor tips. The soluble domain of the high affinity V158 polymorph of FcγRIIIA29 was 
expressed and purified using Pichia pastoris (manuscript in preparation) and binding studies 
using this receptor were conducted as follows. Briefly, an initial baseline was established 
with PBS buffer (50 mM sodium phosphate, 150 mM NaCl, pH = 7.4) and then the protein 
G biosensor tips were loaded with the various IgG1-Fc glycoforms at a concentration of 0.88 
μM in PBS buffer. A new baseline was then established and then the association and 
dissociation of FcγRIIIA was measured in PBS buffer. To determine the dissociation 
constant (Kd) for the IgG1-Fc glycoforms, a range of FcγRIIIA concentrations were tested 
(50 nM, 100 nM, 200 nM, and 400 nM). Data generated from the binding of the receptor to 
IgG1-Fc glycoforms were generated in triplicate and fitted to a 1:1 binding model and 
analyzed using BLITZ Pro software.
Sodium Dodecyl Sulfate-Polyacrylamide Gel Electrophoresis (SDS-PAGE) and 
Western Blot Analysis—Samples containing 20 μg protein, 10μl of a SDS solution, and 
for reduced samples, 5 μl of dithiothreitol (50 mM) were incubated at 80 °C for 2 min and 
loaded onto a NuPAGE 4-12 % Bis-tris gel (Invitrogen, Carlsbad, California) using 20x 
MES as a running buffer. The running time was 65 min at 160V. Gels were then stained 
with Coomassie blue and then destained using 10 % methanol, 10 % glacial acetic acid 
solution. Protein molecular weight standards (BIORAD, Hercules, CA) were loaded for 
molecular weight estimation. Band densitometry measurements were performed using the 
imageJ program (NIH) as described in detail elsewhere.30, 31 For Western blot analysis, 
proteins in SDS-PAGE gels were transferred onto a polyvinylidene fluoride (PVDF) 
membrane (Bio-RAD, Hercules, CA) using 25 mM Tris, 192 mM glycine, 20 % (v/v) 
methanol buffer (pH 8.3). Non-specific binding was blocked (5 % nonfat milk dissolved in 
Tris-buffered saline at pH 7.5, 3 hrs. at 4 °C). The PVDF membranes were washed with 
Tris-buffered saline containing 0.05 % Tween 20 followed by overnight incubation at 4 °C 
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with alkaline phosphatase labeled anti-IgG-Fc specific secondary antibody (Thermo 
scientific, Waltham, MA). Protein bands were visualized by NBT/BCIP substrates (Thermo 
scientific, Waltham, MA).
Size-Exclusion Chromatography (SE-HPLC)—Experiments were performed using a 
Shimadzu high-performance liquid chromatography system equipped with a photodiode 
array detector and a temperature controlled autosampler. A Tosoh TSK-Gel Bioassist 
G3SWxL column (7.8 mm ID × 30.0 cm L) and a corresponding guard column (TOSOH 
Biosciences, King of Prussia, Pennsylvania) were used as described in detail elsewhere.32
Biophysical methods—Far-UV CD spectra ranging from 260 to 205 nm were collected 
in triplicate using a Chirascan spectropolarimeter (Applied Photophysics, Surrey, United 
Kingdom) with 200 μl of a 0.2 mg/ml protein solution in 0.1 cm path length quartz cuvette 
as described in detail elsewhere.24 Intrinsic (Trp) fluorescence was measured in triplicate 
using a Photon Technology International (PTI) Quantum master fluorometer (New 
Brunswick, New Jersey) with 200 μl of a 0.2 mg/ml protein solution in 0.2 cm path length 
quartz cuvette. For thermal stability measurements, the temperature was raised in increments 
of 1.25 °C from 10 to 90°C with a heating rate of 15°/hr. Data were collected and analyzed 
as described in detail elsewhere.24 The maximum peak position (λmax) values were 
calculated using a “spectral center of mass” method (MSM) that causes a red shift in the 
peak position by 10-14 nm compared to the actual value but produces a more reproducible 
measure of spectral shift and a higher signal to noise ratio. 24
Differential Scanning Fluorimetry (DSF) measurements were performed in triplicate using 
MX3005P QPCR system (Agilent Technologies). Samples contained 0.2 mg/ml protein and 
1X SYPRO™ orange dye (Invitrogen, Carlsbad, CA), and data were collected from 25 to 90 
°C using 60 °C/hr a heating rate and then analyzed as described in detail elsewhere.24
Turbidity measurements were performed in triplicate using a Cary 100 UV-Visible 
spectrophotometer (Varian Medical Systems, Inc. Palo Alto, CA) equipped with a 12 cell 
holder with peltier type temperature controller. Samples contained 0.2 mg/ml protein with a 
total volume of 200 μl in 1 cm path length quartz cells. Optical density at 350 nm was 
monitored as the temperature was raised in increments of 1.25 °C from 10 to 90 °C with a 
heating rate of 60°/hr. Corresponding buffer blanks were run and subtracted from each 
sample.
Data visualization techniques—The three-index Empirical Phase Diagram and Radar 
Chart data visualization methods, as described in detail elsewhere,33 were generated using 
in-house software (Middaugh Suite) and then utilized to describe biophysical stability 
characteristics of the various Fc proteins. In this work, three biophysical data sets as a 
function of pH and temperature were used for data visualization: Sypro Orange 
fluorescence, intrinsic Trp peak position fluorescence, and optical density at 350 nm. These 
three techniques were chosen for data visualization since data displayed clear thermal 
transitions; in contrast, circular dichroism thermal stability vs. pH data did not show clear 
thermal transitions (data not shown). For the three index EPDs, the Sypro Orange 
fluorescence stability data were mapped to the color red, Trp fluorescence peak position 
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stability data to the color green, and optical density stability data to the color blue. The 
combination of these RGB values produced a single color at each point in pH and 
temperature coordinates. For each technique and protein, the minimum value was mapped to 
the loss of the color component, and the maximum value was mapped to the full color 
intensity.
The resulting color map was generated: The color black indicates minimum values of all 
three techniques, which can be interpreted as the structure closest to the native state (least 
amount of structural change). The green or red color appears within the three index EPD as 
the Trp fluorescence peak positions changes (displays red shift) or Sypro Orange binding 
increases, respectively. The blue appears when high turbidity is measured by optical density 
values at 350 nm. To determine common regions within the three index EPD, a k-Means 
clustering algorithm is first applied to each EPD to identify boundaries of similarly color 
regions. The resulting clusters can scatter as small blocks of colors, especially over the 
structurally altered regions. Then, using visual assessments and comparisons to the raw 
physical stability profiles for each instrument, only certain commonly observed clusters 
were selected. Radar charts were generated to display similar characteristics (changes in 
readouts from each of the three biophysical instruments) for each of these commonly 
observed clusters. The same three analytical techniques and min-max range were used for 
preparing radar charts. The minimum value was mapped to the center of the radar chart, 
while the maximum value was mapped onto the outer circumference. All values within the 
cluster were averaged from multiple runs and values were connected to yield a final polygon 
to represent a specific structural state.
Results
Initial characterization of the different IgG1-Fc glycoforms
A pictorial presentation of the five different types of IgG1-Fc proteins (diglycosylated, 
monoglycosylated and three different non-glycosylated forms) examined in this study is 
presented in Figure 1. High mannose (HM) IgG1-Fc glycoforms were expressed in yeast and 
purified using a combination of Protein G and cation exchange/hydrophobic interaction 
chromatography. Purified protein fractions of each variant from both cation exchange and 
hydrophobic interaction chromatography were combined to ensure the same material was 
being examined during biophysical studies (see Methods section). Expression of IgG1-Fc in 
Pichia pastoris produced IgG1-Fc with incomplete glycosylation at the Asn 297 site. 
Glycosylation site occupancy is ~ 90% at the Asn 297 site, and since IgG1-Fc is a disulfide-
linked dimer, a mixture of diglycosylated dimer, monoglycosylated dimer and trace amount 
of nonglycosylated dimer is obtained. First, an IgG1-Fc bearing HM glycans at both CH2 
domains of the dimer (~80 % of the amount purified) designated diglycosylated IgG1-Fc 
was identified. Second, an IgG1-Fc containing HM glycan at a single CH2 domain of the 
dimer (~15 % of the amount purified) labeled monoglycosylated IgG1-Fc was found. In 
addition, IgG1-Fc proteins with variations in amino acid residues at site 297 of the CH2 
domain were prepared. IgG1-Fc with Asp/Asp (DD) and Asp/Asn (DN) residues were made 
by treating the diglycosylated and monoglycosylated IgG1-Fc proteins with the enzyme 
PNGase F. PNGase F cleaves the glycan residue(s) and converts Asn to Asp, adding one or 
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two negative charges to the IgG1-Fc molecules (depending on the initial glycosylation site 
occupancy). Finally, a N297Q IgG1-Fc mutant, with Asn/Asn (NN) substituted with 
Gln/Gln (QQ) through site directed mutagenesis, was also expressed and purified (Figure 1).
To confirm the correct masses for each of the purified IgG1-Fc glycoproteins, mass 
spectrometric analysis of reduced samples was performed (Table 1 and supplementary 
Figure S1). The nonglycosylated (QQ) Fc mutant had a mass of 25,077 Da, in close 
agreement (- 3 Da) with the mass predicted from the sequence. MS analysis of 
diglycosylated IgG1-Fc protein revealed a mass of 26,766 Da reflecting a predominant 
Man8GlcNAc2 glycosylation form, in close agreement to the predicted mass (26,770 Da). 
Additionally, peaks corresponding to one, two, three and four additional mannoses were also 
present indicating glycoforms with 9, 10, 11 and 12 mannoses, respectively, but in lower 
abundance (see supplemental Figure S1). The monoglycosylated IgG1-Fc protein had two 
distinct peaks with masses of 25,062 and 26,766 Da in agreement with nonglycosylated and 
Man8GlcNAc2 glycosylated arms of the glycoprotein. A heavier peak reflecting the presence 
of Man9GlcNAc2 IgG1-Fc glycoform was detected as well (see supplemental Figure S1). 
Upon PNGase F enzymatic treatment of the diglycosylated and monoglycosylated IgG1-Fc 
samples, a mass of 25,063 Da was observed for each protein indicating fully deglycosylated 
Fc proteins.
The functionality of the proteins produced in this study was assessed using bio-layer 
interferometry. All IgG1-Fc proteins used in this study were functional in their ability to 
bind protein G as evidenced by the use of protein G affinity chromatography in their initial 
purification and the ability to immobilize all of the purified IgG1-Fc proteins on protein G 
biosensor tips. In addition, those IgG1-Fc glycoforms that are expected to bind to FcγRIIIA 
based on literature reports were indeed functional in that they bound FcγRIIIA. The high 
mannose di-glycosylated IgG1-Fc bound tightly to FcγRIIIA with a Kd of 32 ± 3 nM, as 
would be expected for a non-fucosylated IgG1-Fc glycoform.34, 35 The high mannose 
monoglycosylated IgG1-Fc glycoform bound less tightly with a Kd of 100 ± 8 nM, also as 
would be expected from previous studies.22 PNGase F treated di- and mono-glycosylated 
IgG1-Fc (DD and DN) and mutant IgG1-Fc (QQ) all showed no binding at the highest 
receptor concentration tested which is consistent with previous studies of the importance of 
Fc glycosylation in IgG1 Fc receptor interactions.34
The purity of the various IgG1-Fc glycoproteins was determined under denaturing (SDS-
PAGE and Western Blot) and non-denaturing conditions (SEC) as summarized in Figures 
2A, 2B and 2C, respectively. The di-, mono- and non- glycosylated Fc proteins migrated to 
their expected positions (e.g., under reduced conditions, ~28 kDa, ~28/~26 kDa mixture and 
~26 kDa, respectively) as shown in Figure 2A. Densitometry analysis of the reduced SDS-
PAGE gels showed diglycosylated, nonglycosylated DD, and the nonglycosylated mutant 
(QQ) had ~97-99 % purity. The monoglycosylated Fc protein (and the corresponding 
nonglycosylated DN form derived from PNGase treatment of the monoglycosylated Fc) 
showed somewhat lower purity values of ~84% Visual inspection of the Western blot 
analysis showed high purify levels for all samples and confirmed the PNGase treatment led 
to the expected deglycosylation patterns (Figure 2B). The purity of the IgG1-Fc samples 
under non-denaturing conditions was also determined by SEC (Figure 2C). The 
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diglycosylated Fc protein showed 91.8% vs. 91.1% monomer, and 7.8% vs. 8.2% aggregate 
before and after PNGase treatment. The monoglycosylated Fc protein showed 95.3% vs. 
93.7% monomer, and 3.4% vs. 4.0% aggregate before and after PNGase treatment. The QQ 
aglycosylated mutant showed 96.6% monomer and 1.8% aggregate. The remaining area can 
be accounted for by the presence of small amounts of fragments at the level of ~0.2-2.0% 
(data not shown).
In summary, the monoglycosylated Fc protein, which was only ~15 % of the expressed 
protein, was more difficult to purify compared to the diglycosylated form with more notable 
differences in purity levels (97% vs. 84%) by SDS-PAGE and more minor differences by 
(~92 vs. ~95% monomer) by SEC. PNGase treatment of these samples had minor to no 
effects on the overall protein purity levels, but as expected, removed the oligosaccharides 
from the Fc glycoproteins. Although all of the Fc proteins bind protein G, the asymmetrical, 
monoglycosylated Fc protein showed ~3X decreased functional binding to FcγRIIIA 
receptor while the aglycosylated forms did not bind the same receptor. Similar purity levels 
and functional receptor binding results have been reported recently for an intact 
monoglycosylated mAb 22 (see discussion section). As shown in the next section, the 
asymmetrical monoglycosylated Fc protein displayed notable differences in structural 
integrity and thermal stability as a function of solution pH. .
Structural integrity at ambient temperature conditions
The overall secondary structure of the five IgG1-Fc proteins was evaluated at 10 °C by far-
UV circular dichroism (CD) analysis from 260 to 205 nm under various pH conditions 
(Figure 3). The CD spectra of the diglycosylated IgG1-Fc show a clear minimum at 217 nm 
from pH 5.0-6.0, and to a lesser extent at pH 4.0-5.0, indicating a β-sheet rich structure as 
expected from immunoglobulin folded domains. The same overall β-sheet rich secondary 
structure is seen for the nonglycosylated DD (from PNGase treatment of the diglycosylated 
form) at pH 4.0-4.5, whereas, at pH 5.0, 5.5 and 6.0 a constant decrease in CD signal is 
observed indicating some alteration in the protein secondary structure, under these pH 
conditions, compared to the fully glycosylated form of the protein. Interestingly, for the 
nonglycosylated mutant (QQ) IgG1-Fc, CD spectra show a clear minimum at 217 nm from 
pH 4.0-5.0, and to a lesser extent at pH 5.0-6.0.
For the monoglycosylated IgG1-Fc protein, a different CD spectrum is observed compared 
to the other Fc protein samples with a positive hump present at 212 nm that increases in 
intensity as the solution pH increases. This could potentially be attributed to an increasing 
influence from type I β-turns. When the monoglycosylated IgG1-Fc protein was 
deglycosylated using PNGase F (nonglycosylated DN), more native-like structural features 
in the CD spectra were detected in the form of a minimum at 217 nm in the pH range of 
4.0-5.0, and to lesser extent at pH 5.5 and 6.0. These results indicate the monoglycosylated 
Fc protein is in a structurally perturbed state, and that upon deglycosylation, the effect is at 
least partially reversible with the regaining of native-like secondary structure seen by CD 
(monoglycosylated vs. DN nonglycosylated forms of the Fc protein in Figure 3). The CD 
spectra intensity signals as a function of increasing temperature were monitored. Due to 
noisy data, however, as well as the lack of intensity change as a function of temperature for 
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many of the Fc proteins (e.g., monoglycosylated as well its deglycosylated form), the CD 
thermal melting curves were not further employed in this study (data not shown).
The structural integrity of the overall tertiary structure of the five IgG1-Fc proteins was then 
evaluated using intrinsic (Trp) fluorescence spectroscopy (Figure 4). Diglycosylated and 
nonglycosylated mutant (QQ) IgG1-Fc proteins manifest fluorescence spectra at pH 4.0, 
with relatively high peak intensities, and λmax values of 333.8 and 332.1 nm, respectively. 
As the pH is raised, the λmax starts shifting to lower wavelengths (with λmax values of 329.6 
and 330.6 nm at pH 6.0 accompanied by relatively lower peak intensity), indicating the 
average Trp residues in a more apolar environment, and presumably more folded state. For 
the nonglycosylated DD IgG1-Fc protein, the λmax does not shift to lower wavelength as the 
solution pH is raised, remaining at ~333 nm, suggesting that deglycosylated protein remains 
in the same structure in this pH range, presumably an effect due to deglycosylation and 
amino acid substitution (Asn to Asp at site 297). Monoglycosylated IgG1-Fc protein, 
however, shows a small red shift in λmax as a function of increasing solution pH, indicating 
potentially less folded structure at pH 6.0 (vs. pH 4.0). In addition, the λmax value at pH 6.0 
(337.4 nm) for the monoglycosylated IgG1-Fc is significantly red-shifted by 4-7 nm 
compared to the other samples. Upon PNGase treatment of the monoglycosylated protein, 
the nonglycosylated DN protein is generated and at pH 6.0 shows a more native like λmax 
value of (330.5 nm). It also behaves more like the diglycosylated and QQ nonglycosylated 
mutant with a noticeable blue shift in λmax as the pH is raised from pH 4.0 to 6.0 (~334 to 
~330 nm). These intrinsic fluorescence spectroscopy results, similar to the CD results above, 
indicate that the monoglycosylated Fc protein is in a structurally perturbed state, and that 
upon deglycosylation, the effect is at least partially reversible.
Physical stability of IgG1-Fc proteins as a function of pH and temperature
The conformational stability of the tertiary structure of the five IgG1-Fc proteins was 
evaluated using a combination of intrinsic (Trp) fluorescence and extrinsic fluorescence 
(i.e., differential scanning fluorimetry, DSF) spectroscopy (see Figures 5A, 5B, and 5C with 
the same physical stability data shown in Supplemental Figure S2 with corresponding 
standard deviation error bars from triplicate measurements). The conformational stability of 
the five Fc proteins was first evaluated by following changes in λmax as a function of 
increasing temperature (Figure 5A). It should be noted that the λmax values in Figure 4A are 
mathematically shifted compared to the actual values (see Figure 4), due to the use of a 
spectral central of mass (MSM) method as described in the methods section. Diglycosylated 
and nonglycosylated mutant (QQ) both had relatively low λmax peak positions at the starting 
temperature across the pH conditions tested (~339-340 nm using the MSM method) with 
higher thermal stability being observed for the diglycosylated IgG1-Fc protein. The 
nonglycosylated DD IgG1-Fc protein, with λmax peak positions of ~340 nm, showed a 
subtle, steady increase in peak position as the temperature was raised followed by a more 
dramatic increase in peak position. The monoglycosylated and nonglycosylated DN forms 
(derived from PNGase treatment) had λmax peak positions of ~340-341 nm with little to no 
detectable shift in peak position as the temperature increases, except for the 
monoglycosylated Fc protein at pH 6.0 where a transition curve is detected (Figure 5A).
ALSENAIDY et al. Page 10













In DSF analysis, SYPRO orange dye was used as a probe for detecting structurally disrupted 
proteins, seen in the form of increased fluorescence intensity upon exposure to apolar 
environments due to structural alternations and/or aggregate formation (See Figure 5B). 
Diglycosylated IgG1-Fc was the most thermally stable protein manifesting two thermal 
transitions (presumably sequential unfolding events of the CH2 and CH3 domains). This was 
seen across most of the pH conditions tested (except at pH 4.0) with an observed increase in 
thermal stability as a function of increasing pH. Additionally, fluorescence peak intensity at 
the starting temperature in the range of pH 5.0-6.0 is decreased compared to the values at the 
lower pH conditions. For the monoglycosylated Fc protein at pH between 4.0 and 5.5, and 
nonglycosylated DN protein at pH between 4.0 and 5.0, a single thermal transition is seen, 
consistent with the presence of a more structurally disrupted CH2 domain. Two thermal 
transitions were seen for the nonglycosylated mutant (QQ) and the nonglycosylated DD Fc 
proteins under most of the pH conditions tested, except at pH of 4.0 and 4.5, again 
consistent with the presence of a more structurally altered CH2 domain under lower pH 
conditions (compared to the higher pH range) for these two proteins.
Temperature induced aggregation was evaluated by monitoring optical density changes at 
350 nm as a function of increasing temperature and pH (Figure 5C). Differences between the 
IgG1-Fc proteins were observed in terms of the onset temperature of aggregation as well as 
the profile of the optical density transitions. Diglycosylated IgG1-Fc protein did not show 
detectable thermal transitions in optical density across all pH conditions tested. The 
monoglycosylated Fc protein, on the other hand, displayed a single transition in optical 
density at pH 4.0, 4.5 and 6.0 starting at 21°, 33°, and 76 °C, respectively, whereas, at pH 
5.0 and 5.5, two transitions were detected with the first transitions starting at 45° and 79 °C 
and the second at 52° and 75 °C, respectively. For the nonglycosylated mutant (QQ), a 
single thermal event of increasing optical density was detected at ~79 °C at pH 5.0-6.0, with 
no thermal transitions noted at lower pH values of pH 4.0 and 4.5. Similarly, the 
nonglycosylated DD Fc protein showed no detectable thermal transition at pH 4.0, a single 
thermal transition in optical density starting at 78 °C at pH 4.5, and at 82 °C for pH 5.0, 5.5 
and 6.0. In contrast, the nonglycosylated DN Fc protein (derived from PNGase treatment of 
the monoglycosylated form) manifested two optical density thermal transitions under all pH 
conditions examined. At pH 4.0, the nonglycosylated DN protein showed an increase in 
optical density starting from 10 °C followed by a second major increase at 69 °C. At pH 4.5, 
5.0 and 5.5, an initial increase in optical density was detected at 40°, 46° and 52 °C, 
followed by a second increase at 75°, 78° and 74 °C, respectively. Two adjacent transitions 
in optical density were seen at pH 6.0, with the first transition initiating at 57 °C followed by 
a second transition at 74 °C.
Physical stability evaluations using various data visualization techniques
Using the physical stability data acquired from differential scanning fluorimetry, intrinsic 
fluorescence spectroscopy (peak position), and turbidity measurements, three index EPDs 
and radar charts were constructed for each of the individual IgG1-Fc proteins. A summary 
figure was constructed showing the overall results, from the three-index EPD analysis from 
each of the five individual IgG1-Fc proteins, merged into one display (Figure 6). A 
summary of the radar plot analysis as a function of temperature for each of the five 
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individual IgG1-Fc proteins is provided in supplemental Figure S3. The five color plots in 
Figure 6 highlight five regions with similar structural characteristics designated regions A-E, 
as observed in the three-index EPDs for the five different IgG1-Fc proteins with various 
glycosylation occupancy (diglycosylated, monoglycosylated) as well as the nonglycosylated 
forms of the Fc protein containing amino acid variations (QQ, DD and DN) in the CH2 
domain. In addition, as shown in the legend box in Figure 5, radar plots were prepared to 
better define the five different conformational regions (Regions A through E) that can be 
observed in each of the five Fc proteins under the various pH and temperature conditions.
Region A represents a state in which the IgG1-Fc protein exists in its most native-like 
conformation. As shown in the radar chart legend in Figure 6, there are minimal changes in 
signals for each of the three biophysical techniques (intrinsic Trp and extrinsic SYPRO 
orange fluorescence spectroscopy as well as turbidity at OD 350nm), which results in a 
black color for Region A as shown in the EPDs for the five Fc proteins in Figure 6. For 
Region B, there are small changes in the signals from the biophysical instruments, which 
represents protein with a slightly altered conformation (minor increases in SYPRO orange 
fluorescence intensity and Trp fluorescence peak position) which manifest as a dark green 
color in the EPDs shown in Figure 6. Regions C and D represents more altered 
conformational states with either a substantial increase in SYPRO orange fluorescence 
intensity (Region C as a dark red color) or notable changes in Trp fluorescence peak position 
(Region D as a green color). Finally, Region E represents an aggregated state of the Fc 
protein with increased signal in optical density at 350 nm (see also the radar chart) as shown 
as a blue color in Figure 6.
A comparison of the IgG1-Fc proteins with variations in glycosylation occupancy (see the 
vertical direction in the three color EPD plots on left side of Figure 6) shows different 
degrees of structural integrity and conformational stability. At low temperatures, the 
diglycosylated Fc protein at pH 5.5 and 6.0 is present in a native-like structural state (black 
color, region A). A structural transition to a structurally altered state (dark red, region C) 
starts as Fc diglycosylated Fc protein reaches temperatures around 48 °C in this pH range. 
At lower temperatures in the pH range of 4.5 and 5.0, the diglycosylated Fc protein is 
present in a slightly altered conformation (dark green, region B), where it transitions to a 
more extensive altered structures at temperatures of 38° and 44 °C, respectively. At pH 4.0 
at all temperatures, the diglycosylated protein is present in this more structurally altered 
structural state. Diglycosylated protein did not show any detectable aggregation by optical 
density measurements, thus no Region E was observed in the EPD for the fully glycosylated 
Fc protein.
The nonglycosylated Fc mutant (QQ) at lower temperatures and at pH 5.5 and 6.0 also 
shows a native like region (black color, Region A). Thermal transition temperatures to the 
structurally altered region C (dark red color), however, initiate at lower temperatures (35 and 
44 °C, respectively) compared to the diglycosylated protein (Figure 6). Additionally, the 
nonglycosylated mutant (QQ) at pH 4.5 and 5.0 exists at a more extensively structurally 
altered conformational region, unlike the diglycosylated protein which shows a more native-
like conformation in this pH range (Region B, dark green). In addition, Region E (blue 
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color), representing the Fc protein at an aggregated state is detected for the nonglycosylated 
mutant (QQ) at elevated temperatures in the pH range of 5.0 to 6.0.
In comparison to the di- and non- glycosylated forms, the monoglycosylated Fc protein at 
low temperatures from pH 4.5 to 6.0, exists in a structurally altered Region D (green color) 
as shown in Figure 6. Thus, no native like states (Region A, black color) can be detected. 
The region representing aggregated protein (Region E, blue color) is also seen at high 
temperature for the monoglycosylated Fc. The monoglycosylated Fc protein was the least 
stable compared to the diglycosylated and nonglycosylated (QQ) Fc proteins with no stable 
Region A being detected and with lower temperature thermal transitions noted depending on 
the pH and biophysical readout.
A comparison of the three different nonglycosylated IgG1-Fc proteins with variations in the 
amino acid residue in site 297 (also see Figure 6) also shows different degrees of structural 
integrity and conformational stability. The nonglycosylated DD and nonglycosylated DN Fc 
proteins, containing two and one Asp 297, respectively, were created by PNGase F 
enzymatic treatment of the corresponding di- and mono- glycosylated Fc molecules (See 
Figure 1). The nonglycosylated mutant (QQ) with two Gln residues was also prepared and 
evaluated as a nonglycosylated Fc protein containing an uncharged amino acid residue at the 
297 site. As shown in Figure 6, the nonglycosylated DD IgG1-Fc protein at a pH between 
5.0 and 6.0 exists in an altered state (region D, green color). A small region of aggregated 
protein (region E, blue color) is detected at higher temperature. The aglycosylated DN Fc 
protein shows an enhanced structural integrity at pH 6.0, compared to the nonglycosylated 
DD form where a more native like conformation (region B, dark green) is detected. A 
structurally altered state (region D, green) is observed for the nonglycosylated DN protein at 
pH 5.0 and 5.5 (similar to that seen for the nonglycosylated DD form). A relatively large 
region of aggregated protein (region E, blue color) is present at high temperature for the 
nonglycosylated DN protein, indicating that this form is most prone to aggregation upon 
heating. Finally, the nonglycosylated mutant (QQ), as already discussed above, defines a 
region where the proteins exists in a native-like conformation at pH 5.5 and 6.0 that is not 
seen for the nonglycosylated DD or DN species.
In summary, the presence of a charged amino acid residue at site 297 in the CH2 domain 
(through the conversion of Asn to Asp as a result of the PNGase F enzymatic treatment) had 
a measurable influence on the IgG-1 Fc conformational stability. Comparing the 
nonglycosylated DD to the nonglycosylated mutant (QQ), a stability advantage was detected 
for the nonglycosylated mutant (QQ) with a stable, native like Region A being detected, 
along with higher temperature thermal transitions noted, depending on the pH and the 
method of detection employed. As discussed below, these differences in physical stability 
profiles may not only be due to charge differences of the amino acid residues at site 297, but 
also due to differences in the overall folded state and conformational integrity of the 
different forms.
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Comparability exercises are routinely performed in the biopharmaceutical industry as a 
result of manufacturing process changes (e.g., cell culture or purification steps) or alterations 
in final product presentation (e.g., formulation composition or different packaging material) 
for protein based drugs under development or currently marketed.36, 37 In these studies, the 
critical quality attributes of the pre and post-change protein-drug are evaluated in a head-to-
head fashion to better understand the effect (if any) of the process or product changes on key 
comparability elements such as physiochemical integrity, storage stability, functionality, 
immunogenicity and pharmacokinetics. With regard to physiochemical characterization, 
numerous advances have been made in terms of characterization of a protein's primary 
structure and post translational modifications through multiple chromatographic (size 
exclusion, reverse phase and ion exchange HPLC) and electrophoretic (capillary isoelectric 
focusing and capillary sodium dodecyl sulfate) methods typically applied with mass 
spectrometric detection (intact molecular weight, peptide maps, and oligosaccharides maps). 
Challenges regarding the development of analytical techniques for the structural 
determination of higher order structures still remain, however, resulting in the requirement 
for functional potency assays to ensure biological activity as a surrogate marker to 
demonstrate the protein is properly folded. Although multiple high-resolution analytical 
techniques have been used for the characterization of the higher order structures of proteins, 
ranging from nuclear magnetic resonance (NMR)38, X-ray crystallography39, small angle x-
ray scattering (SAXS) 4 and hydrogen-deuterium exchange mass spectrometry (HDX-
MS),40-43 multiple practical drawbacks such as the requirement of isotope labeling, 
generation of protein crystals, interference of excipients, and/or the complicated and time 
consuming nature of these approaches have limited their use in biocomparability studies.
Alternatively, comparing the physical stability profiles of proteins using lower resolution 
techniques may be a useful complement to these higher sensitivity analytical methods to 
examine subtle differences in protein structure in formulated drug product dosage forms. 
The effect of variations introduced into the glycan structure of an IgG1mAb, through 
enzymatic glycan truncation, protein structural integrity was recently evaluated in our 
laboratory by this alternative approach using more readily available biophysical instruments 
(e.g., fluorescence spectroscopy, light scattering and differential scanning calorimetry).24 By 
using a combination of lower resolution biophysical techniques to study the physical 
stability of mAb glycoforms over a specific pH and temperature range (at 0.5 pH intervals 
from 4-6 and 1.25 °C temperature increments from 10-90°C), combined with recently 
developed data visualization tools, structural and conformational stability differences 
between the different IgG1glycoforms were demonstrated. In the present study, a 
comprehensive evaluation of the overall structural integrity and conformational stability of 
five different IgG1-Fc glycoproteins using multiple biophysical methods across a wide range 
of pH and temperature conditions is undertaken and comparisons are made between their 
corresponding global physical stability profiles (three index EPDs and radar charts).
First, initial characterization of the five well-defined glycoforms of IgG1-Fc (Figures 1 and 
2) was carried out using a combination of mass spectrometry (MS), sodium dodecyl sulfate 
polyacrylamide gel (SDS-PAGE), size exclusion chromatography (SEC) and spectral 
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characterization (CD and fluorescence spectroscopy) to evaluate mass (degree of 
glycosylation), purity and overall structural integrity prior to initiating physical stability 
studies. The five proteins had measured masses in close agreement to their expected masses 
due to their glycosylation status (Table 1). The five proteins were shown to have relatively 
high purity (~91-97%) in primarily monomeric forms as seen from SEC with some 
relatively low levels of aggregation and fragmentation, under non-denaturing conditions. 
Purity under denaturing conditions was analyzed by SDS-PAGE under reduced conditions 
and showed values ranging from ~97-99% for the diglycosylated Fc derived proteins and 
~84% for the monoglycosylated Fc derived proteins. The impurities were further analyzed 
by non-reduced SDS-PAGE and Western Blot analysis (data not shown). One of the minor 
impurity bands was accounted for by the presence of residual PNGase remaining from the 
enzymatically treated Fc samples. The migration of the second minor protein band (~39 
kDa) found in the monoglycosylated derived proteins was not affected by PNGase 
enzymatic treatment or by reduction with DTT (and did not react with the anti-human IgG-
Fc antibody by western blot analysis). This impurity could not be further removed despite 
Protein G affinity purifications combined with cation exchange or HIC columns. These 
differences in the purification behavior between the di- and mono- glycosylated IgG1-Fc 
proteins, along with identification of the minor band at ~39 kDa, are the subject of ongoing 
work in our laboratories. Interestingly, similar to slightly lower purity levels (~80-85%) 
were recently reported for a monoglycosylated IgG1 mAb.22 The lower purity of the 
monoglycosylated forms of IgG-Fc (this work) and IgG1 mAb22 are likely related to the fact 
that the monoglycosylated forms are a minor fraction of the total protein (IgG1-Fc and/or 
IgG1) produced from yeast expression. In this study, the monoglycosylated form is only 
~15% of the total IgG1-Fc produced by yeast expression and displayed structural 
perturbations as well as lower conformational stability; taken together, these attributes 
resulted in significantly more difficulty in purifying this asymmetrical, monoglycosylated Fc 
species compared to the diglycosylated IgG1-Fc. It would be of interest in future work to 
isolate, characterize and compare the soluble aggregates, observed at relatively low levels of 
3.4-7.8% by SEC, from both the diglycosylated and monoglycosylated Fc preparations.
The secondary and tertiary structure of the five proteins using circular dichroism (CD) and 
intrinsic Trp fluorescence spectroscopy was then evaluated (Figures 3 and 4, respectively). 
The diglycosylated and nonglycosylated mutant (QQ) were both present in a more native-
like structure, especially at pH 5-6 (as determined by λmax values and CD minima near 217 
nm). Monoglycosylated Fc at all pH conditions tested was structurally disturbed as indicated 
by the altered CD spectra shape and the red shifted λmax values. Interestingly, upon 
deglycosylation of the monoglycosylated Fc (creating the nonglycosylated DN form), the Fc 
protein showed some recovery of native like secondary structure, more similar to the CD 
spectra of the diglycosylated Fc form with increasing solution pH. This observation further 
supports the hypothesis that somewhat lower purity level of the monoglycosylated Fc does 
not affect the interpretability of the measurements of structure.
IgG1-Fc proteins with varying glycosylation site occupancy showed differences in their 
conformational and colloidal stability with the diglycosylated IgG1-Fc being the most stable 
protein followed by the nonglycosylated mutant (QQ). Perhaps surprisingly the 
monoglycosylated IgG1-Fc manifested the lowest relative physical stability (Figures 5 and 
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6). These observed differences in conformational stability as are consistent with the 
differences in overall secondary and tertiary structures noted at lower temperatures. To the 
best of our knowledge, the effect of Fc glycosylation site occupancy on physical stability has 
only been reported in one limited study by Ha et. al. (2011), which evaluated the thermal 
stability of an asymmetrically glycosylated (single arm glycosylated) IgG1 using one 
method (differential scanning calorimetry) at one pH value (pH 6.0).22 The authors reported 
the CH2 domain of the fully glycosylated IgG1 was thermally more stable than the CH2 
domain of the asymmetrically glycosylated IgG1 by ~1 °C, with no detectable change in 
transition temperatures involving the other domains within the IgG1 protein.
The three index EPDs (Figure 6) and radar charts (supplemental Figure S3) were also able to 
detect similar structural states among the three IgG1-Fc glycoforms with different 
conformational stability profiles. Region A (Black color), where the proteins exist in a more 
native-like conformation as determined by these three biophysical methods, was only 
detected for the diglycosylated and nonglycosylated QQ at pH 5.5 and 6.0. In addition, a 
higher transition temperature to an altered conformational form (Region C) was observed for 
the diglycosylated protein in this pH range. Diglycosylated protein at lower temperatures 
and pH conditions (4.5 and 5.0) was present in a slightly altered conformational state 
(Region B), a conformational state that the nonglycosylated QQ protein doesn't seem to 
access, reflecting the important role glycosylation may play in stabilization of the CH2 
domain in acidic environments.8 Due to fluorescence λmax peak position values shifting to 
higher wavelengths relative to the diglycosylated and nonglycosylated QQ, the 
monoglycosylated Fc protein at pH 5.5 and 6.0 was determined to be present in an altered 
conformational state (Region D). The monoglycosylated Fc protein was then 
deglycosylated, and showed recovery of native like structure under these conditions, further 
indicating the monoglycosylated form has partially altered higher-order structures, the extent 
of which depends on the solution pH examined.
In terms of the effect of amino acid substitution and negative charge introduction at site 297 
in the CH2 domain, the nonglycosylated QQ, DN and DD forms of the IgG1-Fc were 
evaluated using the same biophysical techniques. Compared to the nonglycosylated DD and 
DN forms (with two and one additional Asp residues, respectively), the nonglycosylated 
mutant (QQ) demonstrated increased conformational stability (Figures 5 and 6). However, 
since some differences were noted in the soluble aggregate levels between these 
aglycosylated Fc samples (see Figure 2), future work will need to further evaluate the inter-
relationships between aggregate formation and conformational stability. Additional work 
also is required to further determine if there are any additional differences in the overall 
charge heterogeneity profiles of the five IgG1-Fc samples; initial attempts at peptide 
mapping and capillary isoelectric focusing analysis were unsuccessful due to instability 
during sample preparation (precipitation) and/or lack of reproducibility (data not shown). 
Structural differences under ambient temperature conditions between the nonglycosylated 
IgG1-Fc proteins with variations in amino acid substitutions at site 297 (QQ, DN and DD) 
were detected as well. Nonglycosylated QQ was the only Fc protein that existed at a native-
like conformation (region A) at low temperatures at pH 5.5 and 6.0, whereas, 
nonglycosylated DN and DD both existed in a slightly and more extensively altered forms 
ALSENAIDY et al. Page 16













(Regions B and D) suggesting the important role charge may play in the conformational 
stability of the CH2 domain of these Fc proteins and potentially in mAbs in general.44-46
In summary, by assessing large conformational stability data sets as a function of 
environmental stress (pH, temperature), subtle differences in IgG1-Fc glycoform structural 
integrity were detected. These differences were not readily apparent under non-stressed 
conditions (i.e., lower temperatures at more neutral pH). Thus, the use of conformational 
stability data combined with advanced data visualization methods may be an effective 
surrogate to monitor subtle differences in higher order structure due to post-translational 
modifications such as glycosylation and amino acid substitution/mutation. During analytical 
comparability studies of protein drugs within their pharmaceutical dosage forms, it is 
essential to gather higher order structural information without altering formulation 
conditions (such as protein concentration, pH, ionic strength, excipients, etc.). Biophysical 
analysis of conformational stability using lower resolution techniques in a high throughput 
setup, combined with EPD/radar chart analysis for data visualization, may be a useful 
complement to higher sensitivity analytical methods such as NMR and hydrogen-deuterium 
exchange mass spectrometry to examine subtle differences in protein higher order structure 
in formulated drug product dosage forms.
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Summary of the five different IgG1-Fc proteins examined in this study. The left side shows 
the two glycosylated forms of the Fc protein (diglycosylated and monoglycosylated), while, 
the right side shows the three different nonglycosylated IgG1-Fc protein variants (two from 
PNGase treatment of glycoforms and one point mutant). Identity of amino acid residue at 
site 297 in the CH2 domain (Asn, Asp, Gln) and the nature of glycoforms (Man, mannose 
and GlcNAc, N-acetylglucosamine) are indicated in the figure.
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Purity evaluation of the five Fc proteins under denaturing and non-denaturing conditions. 
SDS-PAGE (A) and Western Blot (B) analysis of reduced IgG1-Fc samples are shown along 
with size exclusion chromatograms (SEC) of the non-reduced IgG1-Fc proteins. See Figure 
1 for nomenclature describing the different IgG1-Fc proteins and text for summary of 
results.
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Far-UV CD spectra from 205-260 nm at 10 °C for the two different Fc glycoforms (di- and 
mono glycosylated) and three different nonglycosylated IgG1-Fc samples (QQ, DD, DN) at 
pH values of 4.0, 4.5, 5.0, 5.5, 6.0. See Figure 1 for a pictorial summary of the five Fc 
proteins examined.
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Intrinsic (Trp) fluorescence spectra at 10 °C for the two different glycosylated (di- and mono 
glycosylated) and three different nonglycosylated forms (QQ, DD, NN) of the IgG1-Fc 
across the pH range of 4.0-6.0. The λmax values are also shown for each protein at each pH 
condition. Each of the samples were run in triplicate and the standard deviation of λmax 
values the ranged from 0.2-0.6 nm. See Figure 1 for pictorial summary of the five Fc 
proteins examined.
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Thermal melting curves for the two different glycosylated (di- and mono glycosylated) and 
three different nonglycosylated forms (QQ, DD, NN) of the IgG1-Fc across the pH range of 
4.0-6.0. Biophysical measurements include (A) Intrinsic Trp fluorescence, (B) Extrinsic 
Sypro Orange fluorescence spectroscopy and (C) optical density at 350 nm. See Figure 1 for 
pictorial summary of the five Fc proteins examined.
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Three index EPDs for the two different glycosylated (di- and mono glycosylated) and three 
different nonglycosylated forms (QQ, DD, NN) forms of the IgG1-Fc. The legend box 
contains radar plots defining the five different conformational stability regions observed in 
the five different Fc proteins. Region A (Black) and B (Dark green) represent regions where 
the protein exists in a native-like and slightly altered structures, respectively. Regions C 
(Dark red) and D (Green) represent regions where the Fc proteins exist at an altered 
structural state as seen from an increase in SYPRO orange and Trp fluorescence signals, 
respectively. Region E (Blue) represents a region where the Fc proteins are in an aggregated 
state as seen by an increased optical density signal.
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